In this article, we will look at the 7 Best Pharma Stocks to Invest In Now.
On March 24, Scott Chronert, Citi, appeared on CNBC’s ‘Closing Bell’ to talk about the market and whether it is time to get into equity markets. He said that there are two stories in the market right now, with the first being on a short-term basis. Positioning had been skewed to the negative over the past three weeks as the Iran conflict unfolded. Therefore, on a short-term basis, any alleviation of the risk around the duration of that conflict is going to be treated with a more positive tone, which is what we have seen in the past day or two, according to him.
READ ALSO: 7 Oversold Stocks to Buy Under $20 AND 8 Affordable Stocks to Buy With Good Earnings Growth.
Chronert further stated that on the flip side, how this ends up playing out over the intermediate terms is a little bit different. Here, we have to continue to keep an eye out for some of the inputs as to where oil prices continue to trade over the intermediate terms, implications for rates, currency, and so forth, and ultimately fundamentals as we go into the fiscal Q1 reporting period.
With these broader market trends in view, let’s look at the best pharma stocks to invest in now.
7 Best Pharma Stocks to Invest In Now
Our Methodology
We used Finviz to make a list of the best pharma stocks and chose the top 7 with the highest number of hedge fund holders as of Q4 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.
Note: All data was recorded on March 30.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7 Best Pharma Stocks to Invest In Now
7. Novartis AG (NYSE:NVS)
Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on March 29 the final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® in IgA nephropathy (IgAN). The company reported that Fabhalta exhibited a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate slope compared with placebo, which is a key marker of kidney function.
The study showed that Fabhalta lowered the likelihood of progression to kidney failure by 43%, with 40.7% of patients on Fabhalta exhibiting sustained reduction of protein in urine over two years. Novartis AG (NYSE:NVS) also stated that Fabhalta consistently showed potential to preserve kidney function in IgAN by showing a slowing of disease progression. Management added that Fabhalta was granted priority review by the FDA for traditional approval.
Vlado Perkovic, MD, Professor of Medicine and Provost, University of New South Wales, and Steering Committee Co‑Chair of the APPLAUSE‑IgAN study, stated that the results are significant because they demonstrate Fabhalta’s ability to “reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden.”
Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare and pharmaceutical products, and is also involved in immuno-oncology research. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.
6. AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) is one of the best pharma stocks to invest in now. AstraZeneca PLC (NASDAQ:AZN) received a rating update from Guggenheim on March 30. The firm lifted the price target on the stock to 16,500 GBp from 16,000 GBp, reiterating a Buy rating on the shares. The rating update came as the firm updated its model ahead of the company’s fiscal Q1 earnings.
In another development, AstraZeneca PLC (NASDAQ:AZN) reported on March 27 positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease. The company stated that tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population. The overall population included former and current smokers, as well as patients across all blood eosinophil counts and all stages of lung function severity. Management added that Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33, and was generally well tolerated with a favourable safety profile.
AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.
While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Pharma Stocks to Invest In Now.
Disclosure: None. Follow Insider Monkey on Google News.
